December 19, 2018
Eisai and Bristol-Myers Squibb have forged a multi-year research collaboration with the aim of capitalizing on an RNA splicing platform owned by the Japanese firm’s US unit, H3 Biomedicine, to develop potential first-in-class immunotherapies with a boosted response against cancer...read more